Skip to content
← All settings

DISEASE & TREATMENT SETTING

Primitive Neuroectodermal Tumor

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Primitive Neuroectodermal Tumor

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 4 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
      source wording
      Source null

      Study evidence for this setting

      8 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00026312 · Source cited / selected · Scope: narrower

      Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

      6 outcome links · 2 safety-group records · 2 quality-of-life measures

      →

      NCT00567567 · Source cited / selected · Scope: narrower

      Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

      6 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT00831844 · Registry condition search · Scope: narrower

      Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

      1 outcome links · 10 safety-group records · 0 quality-of-life measures

      →

      NCT01231906 · Source cited / selected · Scope: narrower

      Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT01767194 · Source cited / selected · Scope: narrower

      Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT02306161 · Source cited / selected · Scope: narrower

      Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT02372006 · Source cited / selected · Scope: narrower

      Trial of Afatinib in Pediatric Tumours

      6 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT03037385 · Source cited / selected · Scope: narrower

      Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

      6 outcome links · 4 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-primitive-neuroectodermal-tumor
        binding id
        ncit-C3716
        source collection
        ncit-concept
        source key
        C3716
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice